Therese Finan, Of Counsel at Burns & Levinson, will lead a panel of industry experts discussing IP out-licensing as a source of revenue, in addition to or as an alternative to raising equity or debt financing. Join to learn more about how to evaluate whether an out-license is the best next step, and issues to consider as you prepare for and approach a licensing deal.

Therese Finan, Of Counsel, Burns & Levinson

Therese Finan has more than 20 years specialized in securing and protecting clients’ intellectual property rights through asset development and management, due diligence, litigation, and licensing while maintaining a focus on the clients’ business objectives. She serves clients from startups to Fortune 50 companies through all phases of the patent process, including preparing patent applications and securing worldwide patent protection, strategically managing patent portfolios while focusing on risk assessment, advising on infringement and validity positions, providing freedom-to-operate analysis, conducting due diligence for business transactions, developing and negotiating licenses, and resolving disputes.

She assists clients in a variety of industries and technologies, primarily in the life sciences industry spanning biotechnology, pharmaceuticals, chemistry, nanotechnology, and medical devices. Her practice is bolstered by her deep background in the biomedical and biotechnology fields, including research in biochemistry, cell biology, and immunology.

Therese also has significant experience counseling clients on trademark matters from developing to securing brand ownership, including procuring and enforcing trademark rights, and resolving domain disputes.

Early in her career, Therese gained experience in public policy and the health care sector.

Ricardo García, CEO & Founder, Oncoheroes Biosciences

Ricardo is a seriel entrepreneur. Passionate about taking on new challenges and with a background in computer engineering and management and business administration, he sold his first company at the age of 22. This led to the creation and development of various companies, predominantly in the field of technology with a strong bent towards innovation.

His son Richi’s brain tumor diagnosis in 2011 forced him to abandon all his plans and move to Boston to save his life. Thankfully that battle has been won, but the fight continues.

After the diagnosis of his son, Ricardo launched the Richi Childhood Cancer Foundation, a 501 (c) (3) non-profit organization established in the US and with links around the world, and Oncoheroes Biosciences, a groundbreaking Boston-based biotech company focused on developing new therapies exclusively for pediatric cancer.

Mark Saulich, Associate Director, Commercialization, Northeastern University

As Associate Director of Commercialization for Northeastern University’s Center for Research Innovation, Mark is focused on advancing Northeastern innovations from lab to market. He and his team build partnerships with industry and support the efforts of Northeastern spinouts. Prior to joining Northeastern, Mark worked as a technology scout at a global open innovation consulting company called yet2.com. He has over 20 years of experience in open innovation and technology transfer.

Sa’ar Yaniv, Director of Business Development, Fortress Biotech

Sa’ar is somewhat of a renaissance man, with experiences ranging from espresso bars, gold mines, and woodworking to frozen yogurt, ski instruction, and bottled water from the Chilean Patagonia

Nevertheless, for the past four years, Sa’ar has been an integral part of the BD&L team at Fortress Biotech, with deals signed in oncology, rare disease, dermatology, and more. Previously, Sa’ar had worked for over 10 years as an equity research analyst at Oppenheimer, JPMorgan, and Roth Capital, among others, and spent over 5 years as a free lance consultant to the life science industry.